Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch

Abstract

Pain is one of the most common clinical symptoms of cancer patients, seriously affecting the quality of life of patients and bringing heavy mental and economic burden to families and society. The treatment of cancer pain in China is facing numerous challenges, one of which includes the irrational usage of analgesic drugs in clinical practice. As a strong opioid analgesic, transdermal fentanyl patch has been widely used due to its convenient clinical application and obvious therapeutic effect. Several basic-level hospitals and even general hospitals in China fail to appropriate the application of drugs in clinical application due to the lack of understanding of the pharmacological characteristics and clinical application of fentanyl transdermal patch by medical staff, seriously affecting the treatment quality. Therefore, it is imperative to strengthen the rational use and management of fentanyl transdermal patches. Accordingly, the initiation by the Cancer Rehabilitation and Palliative Treatment Professional Committee of the Hubei Anti-cancer Association launched the compilation of the “Guidelines for Rational Clinical Use of Fentanyl Transdermal Patch” (from now on referred to as the “Guidelines”) in Hubei Province, China. The experts in the preparation group are experts in many disciplines, such as medicine, pharmacy, and nursing. The expert group determines the outline, prepares the required regulations, and revises it repeatedly. Moreover, these experts put forward suggestions for revision to strictly control the accuracy and scientific authenticity of the contents of the “Guide”. Finally, all experts of the preparation team certify and finalize the draft. This “Guide” prepared by experts of the Cancer Rehabilitation and Palliative Treatment Professional Committee of the Hubei Anti-cancer Association and the expert advisory group with joint efforts, aims to play a positive role in promoting the rational clinical use of fentanyl transdermal patch, reducing the mental and economic burden of patients, and ensuring medical quality and medical safety.

Video abstract

Point your SmartPhone at the code above. If you have a QR code reader the video abstract will appear. Or use:

https://youtu.be/z4dz8su9_Zs

Keywords:

• fentanyl transdermal patch
• reasonable application
• medication guidelines

Statement of Data

The data is available upon reasonable request.

Acknowledgment

Compiling group of “Guidelines for Clinical Rational Use of Fentanyl Transdermal Patch”.

Specially invited consultant

Yu Shiying, Tongji Hospital, Tongji Medical College, HUST; Wei Shaozhong, Hubei Cancer Hospital; Du Guang, Tongji Hospital, Tongji Medical College, HUST.

Committee of Directors

Chen Yuan, Tongji Hospital, Tongji Medical College, HUST.

Members of the expert group

Chu Qian, Tongji Hospital, Tongji Medical College, HUST; Cao Fengjun, SHIYAN RENMIN HOSPITAL; Chen Ping, SHIYAN RENMIN HOSPITAL; Chen Fengju, Tongji Hospital, Tongji Medical College, HUST; Deng Di, ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY; Du Wei, JINGZHOU NO.1 RENMIN HOSPITAL; Duan Chunyan, Enshi Central Hospital; Dai Zhu, Hubei Cancer Hospital; Fan Houwu, Hubei Jianli Traditional Chinese Medicine Hospital; Guo Qinglin, Gong’an Traditional Chinese Medicine Hospital; Hu Zuowei, WUHAN NO.1 HOSPITAL; Ke Hong, Sinopharm Gezhouba Central Hospital; Kuang Li, Dongfeng General Hospital of Sinopharm; Li Linjun, Hubei Integrated Traditional Chinese and Western Medicine Hospital; Li Daojun, Yichang Central People’s Hospital; Liu Xiuli, YICHANG NO.1 RENMIN HOSPITAL; Liu Jing, Huanggang Central Hospital; Luo Xiuli, HUBEI PROVINCIAL HOSPITAL OF TCM; Li Jun, Hubei Xiaogan Central Hospital; Liu Jinmei, Union Hospital, Tongji Medical College, HUST; Li Xin, YICHANG NO.2 RENMIN HOSPITAL; Hu Jianli, Union Hospital, Tongji Medical College, HUST; Ming Bangchun, Shiyan Taihe Hospital; Pan Xianfeng, Jingzhou Central Hospital; Ran Fengming, Hubei Cancer Hospital; Ran Ruizhi, Enshi Central Hospital; Shu Chengrong, Xianning Central Hospital; Sun Jianhai, The Third People’s Hospital of Hubei Province; Tao Weiping, People’s Hospital of Wuhan University; Tang Ze, Huangshi Central Hospital; Wang Jianzhong, Wuhan Iron and Steel Second Hospital; Wang Chun, Wuhan Central Hospital; Wang Qun, Wuhan Fifth Hospital; Wang Huifen, Hubei Cancer Hospital; Xu Shuying, Hubei Cancer Hospital; Yang Bo, Central Theater Command General Hospital; Yin Yifa, YICHANG NO.2 RENMIN HOSPITAL; Yi Tienan, Xiangyang Central Hospital; Zhang Gong, ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY; Zhao Yuanhua, Hubei Cancer Hospital; Zhao Yanxia, Union Hospital, Tongji Medical College, HUST; Zhao Yong, Central Theater General Hospital in Wuhan; Zhang Chengliang, Tongji Hospital, Tongji Medical College, HUST;

Writing group leader

Fu Qiang, Tongji Hospital, Tongji Medical College, HUST.

Writing group members

Han Na, Tongji Hospital, Tongji Medical College, HUST; Li Na, Renmin Hospital of Wuhan University; Gui Ling, Tongji Hospital, Tongji Medical College, HUST; Shi Chen, Union Hospital, Tongji Medical College of HUST; Rong Peipei, People’s Hospital of Wuhan University; Zeng Fan, Tongji Hospital, Tongji Medical College, HUST; Rao He, ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY; Chen Yuan, Tongji Hospital, Tongji Medical College, HUST.

Disclosure

The authors declare that they have no competing interests.

Additional information

Funding

The research received funding from Investigation on standardized treatment of cancer pain (2012) No. YSATTJ-001.